How do Biotechs Stay the Course in Uncharted Waters?
Beyond Borders excerpt: This 32nd edition of our Beyond Borders report offers a chance to take stock of the biotechnology (biotech) industry’s impressive performance during a period of intense global disruption. When, five years ago, we last published our Beyond Borders overview of the sector, we noted the growing geopolitical complexities set to impact biotech. Titling our 2017 report “Staying the course,” we observed that the industry would have to navigate a business environment in which, increasingly, “uncertainty is the only certainty.” From the perspective of 2022, we can affirm that biotech has indeed successfully stayed the course, despite the upheavals that have affected global business since the last edition of this report.
Read the report in its entirety here.
RECENT ARTICLES
Addressing Adenosine: Immunotherapy in the Tumor Microenvironment
Targeting the adenosine axis – components that contribute to the production of adenosine and its subsequent impact – is a promising option.
The Fc-silent Treatment: Pursuing a Known Target in a New Way
We were among the first to take a different approach and pursue an Fc-silent anti-TIGIT antibody based on our own scientific understanding of how this biological pathway works.
